top of page

Good news for newly approved Alzheimer's drug

CMS begins Medicare coverage review for Aduhelm

The CMS announced that it has initiated a National Coverage Determination review process for Biogen's newly approved Alzheimer's disease drug Aduhelm, which could cost $56,000 per year, and it expects to release a proposal within six months and a final determination within nine months. The agency will consider clinical evidence, public comments and guidelines from professional societies when drafting a policy.

Full Story: Reuters (7/12), FierceHealthcare (7/12)

5 views0 comments

Recent Posts

See All

Have your Medicare premiums and copays been breaking your budget? If so, it may be time to talk to us about financial assistance options. Fortunately, there are quite a few, it is possible that you c

PLANAHEAD -- ABOUT 3 MONTHS BEFORE TURNING 65 This is your time to read upon Medicare Parts A, B, and D to familiarize yourself with the basics. You first need to know what Medicare itself does and d

bottom of page